BRIEF-ADC Therapeutics Reports Fourth Quarter And Year-End 2020 Results
BRIEF-ADC Therapeutics Reports Fourth Quarter And Year-End 2020 Results
简介-ADC治疗公司报告2020年第四季度和年终业绩
March 18 (Reuters) - ADC Therapeutics SA :
* Q4 DILUTED LOSS PER SHARE 0.73 USD VERSUS 0.69 USD LOSS YEAR AGO
* QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.73
* QTRLY ADJUSTED NET LOSS PER SHARE, BASIC AND DILUTED $0.82
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* Q4 DILUTED LOSS PER SHARE 0.73 USD VERSUS 0.69 USD LOSS YEAR AGO
* QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.73
* QTRLY ADJUSTED NET LOSS PER SHARE, BASIC AND DILUTED $0.82
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
March 18 (Reuters) - ADC Therapeutics SA :
* Q4 DILUTED LOSS PER SHARE 0.73 USD VERSUS 0.69 USD LOSS YEAR AGO
* QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.73
* QTRLY ADJUSTED NET LOSS PER SHARE, BASIC AND DILUTED $0.82
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
路透3月18日电-ADC Treateutics SA:
*第四季度稀释后每股亏损0.73美元,而一年前亏损0.69美元
*qtrly每股净亏损,基本和稀释后0.73美元
*qtrly调整后每股净亏损,基本和稀释后0.82美元
Eikon的源文本:进一步的公司报道:
(Reurs.Briefs@thomsonreurs.com;)
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧
点击这里分享给好友
暂无评论,快来抢沙发吧!